1. Introduction

Artificial Endocrine Governance Accountability is a proposed interdisciplinary legal framework for regulating artificial or technologically modified systems that influence the human endocrine system. It concerns accountability for the design, testing, manufacture, marketing, clinical use and monitoring of technologies that affect hormones or hormonal functions.

The term is not, by itself, a universally recognized legal doctrine established by a statute or court judgment. Rather, it can be developed as a legal and governance concept by applying existing principles of medical-device regulation, pharmaceutical law, biotechnology governance, informed consent, product liability, privacy, administrative accountability and constitutional rights.

The endocrine system consists of glands and organs that regulate functions through hormones, including growth, metabolism, reproduction, stress responses and other physiological processes. Technologies potentially relevant to this framework include:

Artificial or implantable hormone-delivery systems.

Automated insulin-delivery systems and endocrine monitoring devices.

Hormone-related diagnostic algorithms and clinical decision-support software.

Biotechnologies designed to modify hormone production or signaling.

Digital platforms that recommend or regulate hormone-related treatment.

The central legal question is: Who is legally accountable when an artificial system influences hormonal functions and causes harm, produces discriminatory outcomes, operates without meaningful consent or escapes effective regulatory oversight?

The answer depends on the technology, the jurisdiction, the applicable legislation and the evidence of harm.

2. Meaning and scope of the governance framework

The proposed framework can be divided into three connected elements.

A. Governance

Establishes the rules governing research, clinical trials, approval, deployment, professional supervision and post-market monitoring of endocrine technologies.

B. Accountability

Identifies which manufacturers, developers, healthcare providers, hospitals, regulators or other actors may be responsible for particular failures.

C. Remedies and oversight

Provides mechanisms for investigating incidents, preserving technical records, correcting unsafe systems, compensating injured patients and reviewing unlawful regulatory decisions.

These elements should be considered together. Approval of a technology does not automatically eliminate liability for negligent implementation, defective products, misleading information or failures to respond to newly discovered risks.

3. Legal framework in India

India provides several existing legal routes for governing artificial endocrine technologies. The precise route depends on whether the technology is a medical device, medicinal product, diagnostic system, research intervention or a combination of these.

A. Drugs and Cosmetics Act, 1940 and Medical Devices Rules, 2017

India regulates medical devices through the Drugs and Cosmetics Act, 1940, and the Medical Devices Rules, 2017. The Central Drugs Standard Control Organisation (CDSCO) administers important aspects of this framework. Medical devices are classified according to risk, from Class A (low risk) to Class D (high risk). Software may fall within the medical-device definition when it meets the statutory criteria.

CDSCO

+1

For endocrine governance, this framework is relevant to devices such as hormone-monitoring equipment, implantable delivery systems and automated insulin-delivery systems.

Potential accountability obligations include:

Obtaining the required manufacturing, import or other regulatory authorization.

Demonstrating compliance with applicable safety and performance requirements.

Maintaining appropriate quality-control and traceability systems.

Investigating adverse incidents and taking required corrective action.

Complying with applicable recall, inspection and regulatory directions.

A device that receives authorization is not thereby immune from civil liability if subsequent evidence establishes negligence, a defect or another legally actionable failure.

B. Drugs and clinical-trial regulation

Hormonal medicines, biologics and certain biotechnology-based treatments may be governed by the Drugs and Cosmetics Act and applicable rules, including the New Drugs and Clinical Trials Rules, 2019.

The relevant questions include whether a product has the required approval, whether a clinical investigation was lawfully conducted, whether risks were adequately disclosed, and whether adverse reactions were appropriately monitored and reported.

C. Constitutional principles

Constitutional rights may become relevant where the State, a public hospital or a regulatory authority makes decisions affecting bodily integrity, medical privacy, equality or access to treatment.

Article 21 of the Constitution of India protects life and personal liberty and has been interpreted to encompass important aspects of bodily autonomy, dignity and privacy. Articles 14 and 21 may also constrain arbitrary or inadequately reasoned government decisions affecting access to, or the regulation of, endocrine technologies.

These constitutional principles do not automatically establish a separate constitutional right to every artificial endocrine technology. Their application depends on the facts, the State's involvement and the nature of the alleged violation.

4. Leading case laws and their relevance

The following judgments are established legal authorities that can inform endocrine governance. They are not judgments specifically creating an independent doctrine called “Artificial Endocrine Governance Accountability.”

1. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

Court: Supreme Court of India.

Legal principle: Valid medical consent.

The Supreme Court explained that consent must be voluntary and based on adequate information about the nature and purpose of a proposed treatment, its benefits, available alternatives and material risks. Consent for one procedure does not automatically authorize a substantially different procedure, subject to recognized exceptions.

Application to artificial endocrine governance: If a patient is offered an implantable hormone-delivery system, an experimental endocrine intervention or an automated treatment algorithm, the healthcare provider should explain material risks, limitations, alternatives and the extent of automated decision-making.

A signed consent form alone may not establish valid consent if the patient's understanding was materially deficient or the treatment exceeded the authorization given.

Governance lesson: Informed consent must be a meaningful clinical process, not merely a formality.

2. Jacob Mathew v. State of Punjab, (2005) 6 SCC 1

Court: Supreme Court of India.

Legal principle: Medical negligence and professional standards.

The Court examined the standards for establishing medical negligence and distinguished civil liability from criminal liability. Criminal prosecution of a medical professional for negligence requires the applicable heightened threshold; an adverse outcome alone does not establish criminal negligence.

Application: Suppose a doctor relies on an automated endocrine-management system that delivers an unsafe dose. The legal inquiry would include whether the doctor acted according to the applicable professional standard, whether the system's warnings were ignored, whether reasonable monitoring was undertaken, and whether the harm was causally connected to the alleged breach.

The manufacturer's design or warning failures may require a separate inquiry.

Governance lesson: Accountability should be based on evidence, professional standards and causation rather than the mere fact that a treatment failed.

3. Indian Medical Association v. V.P. Shantha, (1995) 6 SCC 651

Court: Supreme Court of India.

Legal principle: Consumer protection and medical services.

The judgment addressed the application of consumer-protection law to medical services, including the distinction between services provided for consideration and certain categories of free services.

Application: Where the applicable consumer-protection framework covers the relevant healthcare service, a patient harmed by negligent implementation of an endocrine device or inadequate clinical services may have a remedy for deficiency in service. The precise position depends on the service arrangement and the applicable law.

A product defect and a deficiency in clinical service are distinct legal issues, although they may arise from the same incident.

Governance lesson: Healthcare institutions cannot treat the use of advanced technology as a substitute for the quality and safety obligations attached to their services.

4. K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1

Court: Supreme Court of India.

Legal principle: Constitutional protection of privacy.

The Supreme Court recognized privacy as a fundamental right protected by the Constitution. The judgment is particularly relevant to bodily autonomy, informational privacy and personal dignity.

Application: Artificial endocrine systems may collect sensitive information about glucose levels, hormonal patterns, reproductive health, medication adherence and other physiological characteristics. Continuous monitoring and algorithmic inference may create privacy risks beyond those associated with an ordinary medical record.

A governance framework should address lawful collection, purpose limitation, access controls, appropriate security, retention and disclosure of sensitive data.

Governance lesson: Physiological data should not be treated as unrestricted commercial information merely because it is collected by a medical device.

5. Common Cause v. Union of India, (2018) 5 SCC 1

Court: Supreme Court of India.

Legal principle: Patient autonomy and end-of-life decision-making.

The judgment recognized important aspects of patient autonomy in end-of-life medical decisions, including advance directives within the legal framework established by the Court.

Application: This case does not establish a general rule for endocrine devices. However, its broader recognition of autonomy is relevant when treatment involves long-term technological dependence, invasive interventions or decisions about continuing treatment.

Governance lesson: Medical innovation should respect the patient's lawful choices and dignity, while recognizing that the precise consent requirements vary with the treatment and clinical circumstances.

6. Dr. Balram Prasad v. Dr. Kunal Saha, (2014) 1 SCC 384

Court: Supreme Court of India.

Legal principle: Medical negligence, compensation and professional responsibility.

This litigation concerned serious allegations of medical negligence and the assessment of compensation for resulting injury. It illustrates the importance of evidence concerning the standard of care, the causal connection between the alleged negligence and the injury, and the consequences suffered by the patient.

Application: If a manufacturer or hospital deploys an artificial endocrine system that causes serious harm, the evidence may need to address the device's technical performance, the treatment protocol, professional supervision, warnings and the patient's resulting injuries.

The case does not establish automatic liability whenever a medical technology fails. Liability must be determined under the applicable legal principles and evidence.

5. Principal accountability duties

An effective artificial endocrine governance framework should allocate responsibility according to each actor's control over the technology and contribution to the risk.

These responsibilities can overlap. A hospital may be responsible for inadequate monitoring even when a device has a design defect, while a manufacturer may be responsible for a defect that a healthcare professional could not reasonably have detected.

The legal basis for each claim must nevertheless be established separately.

6. Hypothetical case study

Consider an automated hormone-delivery device that measures physiological indicators and adjusts medication through an algorithm.

The system repeatedly misinterprets sensor readings, delivers excessive medication and causes a patient to suffer a serious endocrine emergency.

A court or regulator could examine the following issues:

Product safety: Was the device defective, inadequately tested or improperly labelled?

Software reliability: Were foreseeable sensor errors and algorithmic failures adequately assessed?

Clinical negligence: Did the treating team respond appropriately to warnings and abnormal readings?

Consent: Was the patient informed of material risks, alternatives and relevant limitations?

Causation and damages: Did the alleged failure cause the injury, and what compensation is legally available?

Regulatory accountability: Were applicable incident-reporting, investigation or corrective-action obligations fulfilled?

The evidence could include device logs, software versions, sensor calibration records, medical records, clinical protocols, expert testimony and the manufacturer's risk assessments.

The legal outcome would depend on the applicable statutes, the parties' respective duties and the evidence establishing breach and causation.

7. International regulatory comparison

The United States provides a useful example of technology-specific oversight. The U.S. Food and Drug Administration describes artificial pancreas device systems as combinations of glucose-monitoring technology, insulin-delivery pumps and control algorithms. These systems illustrate how software and physical medical devices can jointly influence a physiological process.

FDA

+1

The FDA also has authority under section 522 of the Federal Food, Drug, and Cosmetic Act to require post-market surveillance for certain Class II and Class III devices.

FDA

This comparison suggests three useful governance principles:

Assess the complete system rather than evaluating hardware and software in isolation.

Continue safety monitoring after market authorization where the applicable law requires it.

Establish mechanisms to investigate incidents and respond to emerging risks.

These US provisions do not apply automatically in India. They serve as comparative examples of regulatory design.

8. Recommended principles for artificial endocrine governance

A comprehensive accountability model could include the following safeguards.

1. Risk-based approval: Require a level of testing and regulatory scrutiny proportionate to the potential severity of endocrine harm.

2. Meaningful informed consent: Explain the purpose, limitations, material risks and alternatives of treatment in language the patient can understand.

3. Human clinical oversight: Ensure that automated recommendations do not eliminate appropriate professional judgment, particularly in emergencies.

4. Technical traceability: Preserve appropriate records of algorithm versions, sensor readings, medication-delivery decisions, alerts and software updates.

5. Post-market monitoring: Investigate adverse events and take corrective action where legally required.

6. Privacy and data protection: Limit the collection, use and disclosure of sensitive endocrine data to lawful and appropriate purposes.

7. Fairness and accessibility: Evaluate whether the technology performs inadequately for particular patient groups or creates unjustified barriers to treatment.

8. Effective remedies: Provide appropriate channels for complaints, regulatory review and compensation where liability is established.

9. Conclusion

Artificial Endocrine Governance Accountability is best understood as a proposed framework that applies established legal duties to technologies affecting hormonal and metabolic functions. It brings together medical-device regulation, product liability, professional negligence, informed consent, privacy and constitutional protections.

The most useful Indian authorities include Samira Kohli, Jacob Mathew, Indian Medical Association v. V.P. Shantha, K.S. Puttaswamy and Common Cause. Together, they provide principles concerning autonomy, professional responsibility, consumer remedies, privacy and dignity.

The essential rule is that technological complexity must not create a gap in legal responsibility. Manufacturers, healthcare providers and public authorities should remain accountable for duties imposed on them by applicable law, even when clinical decisions involve automated systems.

A final qualification is important: no separate, universally established Indian cause of action called “Artificial Endocrine Governance Accountability” has been identified here. Any actual dispute must be assessed under the legislation and precedents applicable to its particular facts.